Unknown

Dataset Information

0

[Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].


ABSTRACT: OBJECTIVE:To explore the efficacy and safety of deferasirox in aplastic anemia (AA)patients with iron overload. METHODS:A single arm, multi- center, prospective, open- label study was conducted to evaluate absolute change in serum ferritin (SF)from baseline to 12 months of deferasirox administration, initially at a dose of 20 mg·kg(-1)·d(-1), and the safety in 64 AA patients with iron overload. RESULTS:All patients started their deferasirox treatment with a daily dose of 20 mg · kg(-1) ·d(-1). The mean actual dose was (18.6±3.60) mg · kg(-1)·d(-1). The median SF decreased from 4 924 (2 718- 6 765)?g/L at baseline (n=64) to 3 036 (1 474- 5 551)?g/L at 12 months (n=23) with the percentage change from baseline as 38%. A median SF decrease of 651 (126-2 125)?g/L was observed at the end of study in 23 patients who completed 12 months' treatment, the median SF level decreased by 1 167(580-4 806)?g/L [5 271(3 420-8 278)?g/L at baseline; 3 036(1 474-5 551)?g/L after 12 months' treatment; the percentage change from baseline as 42% ] after 12 months of deferasirox treatment. The most common adverse events (AEs) were increased serum creatinine levels (40.98%), gastrointestinal discomfort (40.98%), elevated liver transaminase (ALT: 21.31%; AST: 13.11%)and proteinuria (24.59%). The increased serum creatinine levels were reversible and non-progressive. Of 38 patients with concomitant cyclosporine use, 12(31.8%)patients had two consecutive values >ULN, 10(26.3%)patients had two consecutive values >1.33 baseline values, but only 1(2.6%)patient's serum creatinine increased more than 1.33 baseline values and exceeded ULN. For both AST and ALT, no patients experienced two post- baseline values >5 ×ULN or >10 × ULN during the whole study. In AA patients with low baseline PLT count (less than 50 × 10(9)/L), there was no decrease for median PLT level during 12 months' treatment period. CONCLUSIONS:AA patients with iron overload could achieve satisfactory efficacy of iron chelation by deferasirox treatment. The drug was well tolerated with a clinically manageable safety profile and no major adverse events.

SUBMITTER: Shi J 

PROVIDER: S-EPMC7342302 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

[Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].

Shi Jun J   Chang Hong H   Zhang Li L   Shao Yinqi Y   Nie Neng N   Zhang Jing J   Huang Jinbo J   Zhang Li L   Tang Xudong X   Quan Richeng R   Zheng Chunmei C   Xiao Haiyan H   Hu Dengming D   Hu Lingyan L   Liu Feng F   Zhou Yongming Y   Zheng Yizhou Y   Zhang Fengkui F  

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20160101 1


<h4>Objective</h4>To explore the efficacy and safety of deferasirox in aplastic anemia (AA)patients with iron overload.<h4>Methods</h4>A single arm, multi- center, prospective, open- label study was conducted to evaluate absolute change in serum ferritin (SF)from baseline to 12 months of deferasirox administration, initially at a dose of 20 mg·kg(-1)·d(-1), and the safety in 64 AA patients with iron overload.<h4>Results</h4>All patients started their deferasirox treatment with a daily dose of 20  ...[more]

Similar Datasets

| S-EPMC6483623 | biostudies-literature
| S-EPMC7202239 | biostudies-literature
| S-EPMC5969382 | biostudies-literature
| S-EPMC6772897 | biostudies-literature
| S-EPMC6355477 | biostudies-literature
| S-EPMC6489379 | biostudies-literature
| S-EPMC4490296 | biostudies-literature
| S-EPMC3696607 | biostudies-literature
| S-EPMC4430492 | biostudies-literature
| 2100588 | ecrin-mdr-crc